137 related articles for article (PubMed ID: 17704947)
1. Enhancement of erbB2 and erbB3 expression during oral oncogenesis in diabetic rats.
Vairaktaris E; Goutzanis L; Vassiliou S; Spyridonidou S; Nkenke E; Papageorgiou G; Strantzias P; Lazaris A; Yapijakis C; Patsouris E
J Cancer Res Clin Oncol; 2008 Mar; 134(3):337-44. PubMed ID: 17704947
[TBL] [Abstract][Full Text] [Related]
2. Diabetes enhances the expression of H-ras and suppresses the expression of EGFR leading to increased cell proliferation.
Vairaktaris E; Goutzanis L; Yapijakis C; Vassiliou S; Spyridonidou S; Vylliotis A; Nkenke E; Lazaris AC; Strantzias P; Patsouris E
Histol Histopathol; 2009 May; 24(5):531-9. PubMed ID: 19283661
[TBL] [Abstract][Full Text] [Related]
3. Abundance and localization of skeletal muscle-related erbB2 may stimulate tumour growth during initial stages of oral oncogenesis.
Vairaktaris E; Moulavassili P; Loukeri S; Spyridonidou S; Yapijakis C; Vassiliou S; Nkenke E; Vylliotis A; Papakosta V; Lazaris A; Patsouris E
J Musculoskelet Neuronal Interact; 2007; 7(2):185-90. PubMed ID: 17627089
[TBL] [Abstract][Full Text] [Related]
4. Diabetes enhances cell proliferation but not Bax/Bcl-2-mediated apoptosis during oral oncogenesis.
Vairaktaris E; Kalokerinos G; Goutzanis L; Yapijakis C; Derka S; Vassiliou S; Spyridonidou S; Vylliotis A; Nkenke E; Lazaris A; Patsouris E
Int J Oral Maxillofac Surg; 2008 Jan; 37(1):60-5. PubMed ID: 17825529
[TBL] [Abstract][Full Text] [Related]
5. Increased risk of oral cancer in diabetic animals is not associated with c-jun activation pathway.
Vairaktaris E; Goutzanis L; Kalokerinos G; Vassiliou S; Spyridonidou S; Avgoustidis D; Strantzias P; Lazaris A; Papageorgiou G; Ragos V; Yapijakis C; Patsouris E
J Craniomaxillofac Surg; 2007 Dec; 35(8):382-7. PubMed ID: 18023197
[TBL] [Abstract][Full Text] [Related]
6. Diabetes and oral oncogenesis.
Vairaktaris E; Spyridonidou S; Goutzanis L; Vylliotis A; Lazaris A; Donta I; Perrea D; Yapijakis C; Patsouris E
Anticancer Res; 2007; 27(6B):4185-93. PubMed ID: 18225590
[TBL] [Abstract][Full Text] [Related]
7. Diabetes increases both N-ras and ets-1 expression during rat oral oncogenesis resulting in enhanced cell proliferation and metastatic potential.
Vairaktaris E; Goutzanis L; Kalokerinos G; Yannopoulos A; Yapijakis C; Vassiliou S; Spyridonidou S; Vylliotis A; Nkenke E; Lazaris AC; Tesseromatis C; Patsouris E
In Vivo; 2007; 21(4):615-21. PubMed ID: 17708355
[TBL] [Abstract][Full Text] [Related]
8. Diabetes alters expression of p53 and c-myc in different stages of oral oncogenesis.
Vairaktaris E; Kalokerinos G; Goutzanis L; Spyridonidou S; Vassiliou S; Derka S; Nkenke E; Yapijakis C; Vylliotis A; Lazaris A; Patsouris E
Anticancer Res; 2007; 27(3B):1465-73. PubMed ID: 17595763
[TBL] [Abstract][Full Text] [Related]
9. Diabetes does not influence oral oncogenesis through fibroblast growth factor receptors.
Vairaktaris E; Goutzanis L; Nkenke E; Spyridonidou S; Vassiliou S; Derka S; Vylliotis A; Yapijakis C; Lazaris A; Strantzias P; Kalimeras E; Patsouris E
In Vivo; 2007; 21(4):623-8. PubMed ID: 17708356
[TBL] [Abstract][Full Text] [Related]
10. The hamster model of sequential oral oncogenesis.
Vairaktaris E; Spyridonidou S; Papakosta V; Vylliotis A; Lazaris A; Perrea D; Yapijakis C; Patsouris E
Oral Oncol; 2008 Apr; 44(4):315-24. PubMed ID: 18061531
[TBL] [Abstract][Full Text] [Related]
11. Expression of cell cycle regulator p16 is not affected by diabetes during oral oncogenesis.
Vairaktaris E; Goutzanis L; Nkenke E; Spyridonidou S; Vassiliou S; Derka S; Vylliotis A; Yapijakis C; Lazaris A; Patsouris E
In Vivo; 2007; 21(5):745-50. PubMed ID: 18019407
[TBL] [Abstract][Full Text] [Related]
12. Changes in ErbB2 (her-2/neu), ErbB3, and ErbB4 during growth, differentiation, and apoptosis of normal rat mammary epithelial cells.
Darcy KM; Zangani D; Wohlhueter AL; Huang RY; Vaughan MM; Russell JA; Ip MM
J Histochem Cytochem; 2000 Jan; 48(1):63-80. PubMed ID: 10653587
[TBL] [Abstract][Full Text] [Related]
13. Co-localization of multiple ErbB receptors in stratified epithelium of oral squamous cell carcinoma.
Bei R; Pompa G; Vitolo D; Moriconi E; Ciocci L; Quaranta M; Frati L; Kraus MH; Muraro R
J Pathol; 2001 Oct; 195(3):343-8. PubMed ID: 11673832
[TBL] [Abstract][Full Text] [Related]
14. Cell proliferation and apoptosis culminate in early stages of oral oncogenesis.
Derka S; Vairaktaris E; Papakosta V; Vassiliou S; Acil Y; Vylliotis A; Spyridonidou S; Lazaris AC; Mourouzis C; Kokkori A; Moulavasili P; Perrea D; Donta I; Yapijakis C; Patsouris E
Oral Oncol; 2006 May; 42(5):540-50. PubMed ID: 16464633
[TBL] [Abstract][Full Text] [Related]
15. Constitutive expression of erbB2 in epidermis of transgenic mice results in epidermal hyperproliferation and spontaneous skin tumor development.
Kiguchi K; Bol D; Carbajal S; Beltrán L; Moats S; Chan K; Jorcano J; DiGiovanni J
Oncogene; 2000 Aug; 19(37):4243-54. PubMed ID: 10980598
[TBL] [Abstract][Full Text] [Related]
16. Diabetes may increase risk for oral cancer through the insulin receptor substrate-1 and focal adhesion kinase pathway.
Goutzanis L; Vairaktaris E; Yapijakis C; Kavantzas N; Nkenke E; Derka S; Vassiliou S; Acil Y; Kessler P; Stavrianeas N; Perrea D; Donta I; Skandalakis P; Patsouris E
Oral Oncol; 2007 Feb; 43(2):165-73. PubMed ID: 16860589
[TBL] [Abstract][Full Text] [Related]
17. Zinc finger transcription factors designed for bispecific coregulation of ErbB2 and ErbB3 receptors: insights into ErbB receptor biology.
Lund CV; Popkov M; Magnenat L; Barbas CF
Mol Cell Biol; 2005 Oct; 25(20):9082-91. PubMed ID: 16199884
[TBL] [Abstract][Full Text] [Related]
18. Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.
Kim A; Liu B; Ordonez-Ercan D; Alvarez KM; Jones LD; McKimmey C; Edgerton SM; Yang X; Thor AD
Breast Cancer Res; 2005; 7(5):R708-18. PubMed ID: 16168116
[TBL] [Abstract][Full Text] [Related]
19. Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth.
Yen L; Cao Z; Wu X; Ingalla ER; Baron C; Young LJ; Gregg JP; Cardiff RD; Borowsky AD; Sweeney C; Carraway KL
Cancer Res; 2006 Dec; 66(23):11279-86. PubMed ID: 17145873
[TBL] [Abstract][Full Text] [Related]
20. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT.
Bruzzese F; Leone A; Rocco M; Carbone C; Piro G; Caraglia M; Di Gennaro E; Budillon A
J Cell Physiol; 2011 Sep; 226(9):2378-90. PubMed ID: 21660961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
